Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of MK0869 (Aprepitant) in Major Depressive Disorder
NCT00034983Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2001
- Primary completion
- Dec 2003
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of aprepitant in major depressive disorder (MDD), sponsored by Merck & Co.. Started Oct 2001; status: completed.
02
Drugs
aprepitant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00034983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034983.